Dr. Nowakowski on Potential Clinical Implications of the ENGINE Study in DLBCL
August 12th 2020Grzegorz S. Nowakowski, MD, discusses the potential clinical implications of the ongoing, randomized phase 3 ENGINE study in patients with high-risk Denovo Genomic Marker 1–positive diffuse large B-cell lymphoma.
Read More
Dr. Nowakowski on Using Patient Performance Score and Age for MCL Treatment
August 28th 2017Grzegorz S. Nowakowski, MD, assistant professor of medicine at Mayo Clinic, discusses the use of patient performance status and age to make treatment decisions for patients with mantle cell lymphoma (MCL).
Read More
Dr. Nowakowski on Biological Heterogeneity in Newly Diagnosed Patients With MCL
August 16th 2017Grzegorz S. Nowakowski, MD, assistant professor of medicine at Mayo Clinic, discusses the desire to use biological heterogeneity as a factor for treatment in newly diagnosed patients with mantle cell lymphoma (MCL).
Read More